COVID-19 has swept the world, and while some people may experience long-term cognitivedecline as a result of infection, no effective treatment has been announced. The primarygoal of this study was to determine the efficacy of hyperbaric oxygen therapy in patientswith SARS-CoV-2 infection, as well as to assess the effect of hyperbaric oxygen therapyon brain function in patients with COVID-19-related cognitive decline. In this study,approximately 80 people were randomly assigned to either hyperbaric oxygen or regularoxygen therapy to compare the effects of these two treatments on disease.
80 patients with cognitive impairment following a novel coronavirus infection will be
randomly assigned to one of two treatment groups: hyperbaric oxygen therapy or
conventional oxygen therapy.
After the intervention, the improvement of hyperbaric oxygen on cognition, fatigue, sleep
disorders, anxiety and depression, and other clinical manifestations was observed. The
neurologic function of hyperbaric oxygen in the treatment of patients with cognitive
decline after SARS-CoV-2 infection was also evaluated from imaging and
electrophysiological multi-dimensional indexes.
Procedure: hyperbaric oxygen therapy
The hyperbaric oxygen group was given 60 minutes of pure oxygen under 2ATA (Atmosphere
Absolute, ATA) and 5 minutes of rest in between.
Procedure: conventional oxygen therapy
Conventional oxygen therapy group breathed 27% oxygen at 1.03 ATA for 60 minutes. (The
chamber pressure was increased to 1.2ATA with circulating air noise for the first 5
minutes of the experiment, then reduced to 1.03 ATA for the next 5 minutes.)
Inclusion Criteria:
- Out-patients 4 weeks after the diagnosis of SARS-CoV-2 infection
- Subjective cognitive decline after SARS-CoV-2 infection
- SARS-CoV-2 nucleic acid/antigen test negative.
Exclusion Criteria:
- Contraindications to hyperbaric oxygen therapy
- Cognitive decline can be explained by other diseases
- Conditions that researchers consider unsuitable for clinical trials.
First Affiliated Hospital of Zhejiang Chinese Medical University
Hangzhou, Zhejiang, China
Investigator: Jiannong Wu, M.D.
Contact: 13777571598
13777571598@163.com
Investigator: Chenjuan Wang, M.M.
Yan Jiang, M.D.
13575757710
jiangyan@zcmu.edu.cn
Shan Liu, M.M.
18806715135
graystar92@163.com
Jiannong Wu, M.D., Study Chair
First Affiliated Hospital of Zhejiang Chinese Medical University